Prevalent Metformin Use in Adults With Diabetes and the Incidence of Long COVID: An EHR-Based Cohort Study From the RECOVER Program
Authors' conclusion
Prevalent metformin use is associated with a slightly lower incidence of death or PASC after SARS-CoV-2 infection. PASC incidence by computable phenotype is higher than by EHR code, especially in PCORnet. These data are consistent with other observational analyses showing prevalent metformin is associated with favorable outcomes after SARS-CoV-2 infection in adults with T2DM.
Study context
- Population
- Adults with T2D (HbA1c ≥6.5 or T2D electronic health record (EHR) diagnosis code) with SARS-CoV-2 infection, N3C and PCORnet EHR databases
- Exposure
- Prevalent metformin use vs other diabetes medications
- Outcome
- Death or PASC, defined by EHR code or computable phenotype
- Follow-up
- Within 6 months
Methodological detailsactive comparator design, EHR-based, N3C and PCORnet databases
- Active comparator design
- EHR-based
- N3C and PCORnet databases
Main finding
As reported in the abstract
N3C: HR for death or PASC-U09.9 (U09.9 diagnosis code)
0.79
95% CI 0.71–0.88P < 0.001
N3C: HR for death or PASC-N3C (N3C computable phenotype)
0.85
95% CI 0.78–0.92P < 0.001
PCORnet: HR for death or PASC-U09.9
0.87
95% CI 0.66–1.14P = 0.08
PCORnet: HR for death or PASC-PCORnet (PCORnet computable phenotype)
1.04
95% CI 0.97–1.11P = 0.58
Observational data: associations, not effects.
Further findings
Incident PASC by diagnosis code, N3C
Incident PASC by diagnosis code, PCORnet
Incident PASC by computable phenotype, N3C
Incident PASC by computable phenotype, PCORnet
Original publication
Composed by AI from the published abstract and checked against it. How Briefs are made →